Testing high-dose cyclophosphamide to treat adult HLH
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial studies whether giving high-dose cyclophosphamide as an initial treatment works better for adults with HLH. HLH is a serious, overactive immune condition, and the study aims to improve control of the illness and safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 65 years old.
- You have HLH based on HLH-2004 criteria (genetic confirmation or meeting at least 5 of the main signs).
- Your HLH is not caused by an infection that can be treated (except Epstein-Barr virus).
- You can understand the study, follow the plan, and sign consent.
- You are able to tolerate large doses of cyclophosphamide (not extremely weak and with stable vital signs).
- You do not have major uncontrolled illnesses or serious organ damage from long-term disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults who have findings that suggest HLH, a serious immune problem. It may help doctors better understand the condition by tracking patients over time and comparing symptoms and test results.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial tests whether a short course of two medicines, dexamethasone (a steroid) and intravenous immunoglobulin (antibodies from donated blood), can help treat a rare condition called hemophagocytic lymphohistiocytosis (HLH) that is triggered by an infection. It may help control the body's overactive immune response and improve organ function.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
This study is testing a modified treatment regimen (called DEP) with or without the drug ruxolitinib for patients with HLH, a serious condition where the immune system attacks the body. The goal is to see if this combination is safe and helps control the disease.
This trial tests a combination of two drugs, emapalumab and ruxolitinib, for people with hemophagocytic lymphohistiocytosis (HLH), a rare condition where the immune system becomes overactive and damages organs. The goal is to control the disease with fewer side effects than standard treatments.
Hear when a new Hemophagocytic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.